Evidence map›Paper›PMID 40750722›Full record

ArticleJournal of cancer survivorship : research and practice2026

Neurocognitive concerns and neurocognitive impairment in long-term survivors of oropharyngeal cancer post (chemo)radiotherapy.

Zsuzsanna Iyizoba-Ebozue, Robin Prestwich, Maryse Luijendijk, Emma Nicklin, Chinyereugo Umemneku-Chikere, Stuart Currie, James Price, Sarah R Brown, Emma Hall, John Lilley and 6 more

Abstract readMulticenter Study
In one paragraph

Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Comment on "Communication and fear of cancer recurrence in colorectal cancer survivors and their partners".Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zsuzsanna Iyizoba-EbozueDepartment of Clinical Oncology, Leeds Cancer Centre, St. James's University Hospital, Beckett St, Level 4, Bexley Wing, Leeds, LS9 7TF, UK. Zsuzsanna.iyizoba@nhs.net.ORCID http://orcid.org/0000-0002-9839-4532
Robin PrestwichDepartment of Clinical Oncology, Leeds Cancer Centre, St. James's University Hospital, Beckett St, Level 4, Bexley Wing, Leeds, LS9 7TF, UK.
Maryse LuijendijkDivision of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Emma NicklinLeeds Institute of Medical Research, University of Leeds, Leeds, UK.
Chinyereugo Umemneku-ChikereCenter for Review and Dissemination, University of York, York, UK.
Stuart CurrieDepartment of Neuroradiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
James PriceDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Sarah R BrownLeeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, Leeds, UK.
Emma HallClinical Trials and Statistics Unit, Institute of Cancer Research, London, UK.
John LilleyMedical Physics and Engineering, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Matthew LoweChristie Medical Physics and Engineering, The Christie NHS Foundation Trust, Manchester, UK.
Marcus TyygerMedical Physics and Engineering, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
David J ThomsonDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Finbar SlevinDepartment of Clinical Oncology, Leeds Cancer Centre, St. James's University Hospital, Beckett St, Level 4, Bexley Wing, Leeds, LS9 7TF, UK.
Louise Murray *Department of Clinical Oncology, Leeds Cancer Centre, St. James's University Hospital, Beckett St, Level 4, Bexley Wing, Leeds, LS9 7TF, UK.
Florien Boele *Leeds Institute of Medical Research, University of Leeds, Leeds, UK.

Funding

Cancer Research UK 95653122/95653121Cancer Research UK RRCOER-Jun24/100004Yorkshire Cancer Research L389LM
6 · The paper itself

Abstract

backgroundLittle is known about neurocognitive concerns (NCC) and neurocognitive function (NCF) in survivors of oropharyngeal cancer (OPC) following (chemo)radiotherapy.

methodsA multicentre cross-sectional study was conducted in non-surgically treated OPC. Using the Medical Outcomes Study Cognitive Functioning Scale (MOS-Cog), NCC were classed as having concerns at least some of the time (MOS-Cog score of ≤ 60 across all items). Patients were also invited to complete an online cognitive test battery (Amsterdam Cognition Scan; ACS) to assess NCF. Using norm scores from 708 individuals from the UK general population, significant NCF impairment was defined as Z score ≤  - 2 in one domain or ≤  - 1.5 in at least two domains. Regression analysis was performed to identify factors associated with NCC/NCF.

resultsThree hundred thirty-eight patients treated for OPC, with median age at treatment of 58.6 years and median follow-up of 6 years (IQR 4-8) post-treatment, were recruited. NCC were present in 14.8% of patients. Amongst 93 patients who completed the ACS, 33% demonstrated significant impairment in NCF. Memory and attention were the most affected domains in NCC and NCF. On multivariable regression analysis, mental fatigue, mood, general fatigue, and physical fatigue significantly predicted NCC. Multivariate analysis revealed a small but statistically significant negative association between mood and NCF. No statistically significant correlations were found between NCC/NCF impairment and radiation dose received by the posterior fossa.

conclusionNCC and NCF impairment affects a substantial proportion of long-term survivors of OPC. Assessment of NCC and NCF is essential for a comprehensive understanding of cognitive health in this population. IMPLICATIONS FOR CANCER SURVIVORS: This study highlights that a substantial proportion of long-term oropharyngeal cancer survivors experience both subjective NCC and objective NCF impairment. The findings underscore the need for neurocognitive screening and a multidisciplinary approach to survivorship care, incorporating psychological and cognitive support alongside traditional follow-up.

Indexed as

Cancer SurvivorsChemoradiotherapyNeurocognitive DisordersOropharyngeal NeoplasmsAgedCross-Sectional StudiesFemaleHumansMaleMiddle AgedNeuropsychological TestsAmsterdam Cognition ScanNeurocognitionOropharyngeal cancersRadiotherapySurvivorship

Identifiers

PMID40750722
PMCPMC13676501

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.